Unnatural Products Inc. is a biotechnology company developing orally-delivered macrocyclic peptides to address challenging therapeutic targets.
Subscribe to see Unnatural Products’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Unnatural Products is a business and productivity company headquartered in United States. It has raised at least $81.1M across the 4 funding rounds on record. Its most recent funding round, Series B, raised $45M in March 2026. Xcout tracks 12 named people at Unnatural Products, including Simon Bailey (Chief Operating Officer and President of Research and Development).
6 more named people on record for Unnatural Products, with roles, board committees and tenure — see the full roster →
At least $81.1M raised across the 4 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $45M | 6 named | |
| Series B | $6M | 8 named | |
| SEC Form D filing | $25M | — | |
| SEC Form D filing | $5.1M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Unnatural Products's closest competitors — see the full list of competitors and alternatives →
Nephrogen is a preclinical biotechnology company founded in 2022 and headquartered in New York, NY. The company is dedicated to developing curative genomic medicines for patients suffering from serious diseases.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.